STAT Plus: Architects of a new CRISPR partnership defend academic-industry research model
SAN FRANCISCO — With a new deal to use CRISPR to hunt for new drugs, the drug maker GlaxoSmithKline and the leading academic gene-editing researchers it’s collaborating with are embarking on a first-of-its-kind partnership.
But the collaboration raises questions that are familiar to many partnerships between academic and industry researchers: What will each party get out of the deal? What will get published? And will GSK exert undue influence on what gets studied?
Continue to STAT Plus to read the full story…
